[Drug-induced subacute cutaneous lupus erythematosus: repeated occurrence following treatment with terbinafine].
A woman developed subacute cutaneous lupus erythematosus (SCLE) in 1995 and 2013, each time 6 weeks after initiation of terbinafine therapy. Within the heterogeneous group of drug-induced SCLE terbinafine is considered the most common cause. The clinical, histopathological and laboratory findings of idiopathic and drug-induced SCLE are largely identical. The pathogenesis of drug-induced SCLE is not known. Cytotoxic and immunological mechanisms are considered likely. The treatment of drug-induced SCLE is discontinuation of the suspected drug. In addition, corticosteroids are recommended alone or in combination with chloroquine or hydroxychloroquine.
Klinik für Dermatologie, Allergologie und Phlebologie, Klinikum Bremerhaven Reinkenheide, Postbrookstr. 103, 27574, Bremerhaven, Deutschland, gunnar.wagner@klinikum-bremerhaven.de.
G
G
Wagner
M M
MM
Sachse
D000328:Adult; D000935:Antifungal Agents / Q000009:adverse effects; D005260:Female; D006801:Humans; D008178:Lupus Erythematosus, Cutaneous / Q000139:chemically induced* / Q000175:diagnosis* / Q000517:prevention & control; D009281:Naphthalenes / Q000009:adverse effects*; D012008:Recurrence; D000077291:Terbinafine; D016896:Treatment Outcome
D000935:Antifungal Agents; D009281:Naphthalenes; D000077291:Terbinafine